Growth Business

NOVEMBER 2, 2023

Unlike standard venture capital firms, CVCs work a lot closer with their portfolio companies in developing a particular technology that is beneficial to both parties. It is interested in companies at pre-Series A through to pre-IPO stage. Here, we list active CVCs in the UK, what they look for and how much they invest.

Corporation 52

Corporation Capital Investment Media 52

Cooley M&A

SEPTEMBER 16, 2022

There are compelling rationales for adopting a dual-class structure, but even proponents of the structure generally acknowledge that these benefits are significantly mitigated once the dual-class shares are out of the hands of the founders and/or pre-IPO stockholders. Potential carve outs for M&A voting agreements. Stockholder litigation.

M&A 59

M&A IPO Shares Mergers and Acquisitions 59

Growth Business

SEPTEMBER 13, 2023

DN Capital’s previous funds are top performers and the firm is one of the lead investors in companies such as Endeca (sold to Oracle), Shazam (one of the world’s leading mobile app), Auto1 (world’s largest used car marketplace), Purplebricks (IPO London) and Quandoo (sold to Recruit).

Capital 52

Capital Business Funds Investment 52

Mergers and Inquisitions

APRIL 10, 2024

The Top Sports Private Equity Firms The list of sports PE firms was short in 2015, but it has exploded over time. And yes, I’m aware of Steve Cohen, David Tepper, and Steve Balmer, but they’re all single-team owners , which is a bit different than owning a portfolio of sports teams. How Do Sports Private Equity Deals Work?

Private Equity 103

Private Equity Equities Funds Entertainment 103

Focus Investment Banking

FEBRUARY 11, 2025

Overcoming Marketplace Uncertainty Rising interest rates introduced a difficult environment for private equity recapitalizations (where private equity groups sell a portfolio company to another buyer), so few of the older PE-backed ophthalmology organizations traded hands over the last few years.

Private Equity 52

Private Equity Healthcare Equities Medical 52

Cooley M&A

FEBRUARY 1, 2024

Private equity slowed but not stopped by financing environment Despite record amounts of dry powder accumulating for sponsors, high financing costs, persistent valuation gaps and a closed tech IPO market led to a significant decrease in private equity M&A activity in 2023. Despite some isolated bright spots – such as Thoma Bravo’s $10.7

M&A 59

M&A Mergers and Acquisitions Private Equity Equities 59